CATALYST PHARMACEUTICALS, INC. 4

Donald A. Denkhaus disposed of 498,773 common shares plus all outstanding stock options and RSUs of Catalyst Pharmaceuticals, Inc. for cash at the $31.50 per-share merger price in the Angelini Pharma acquisition.

On July 15, 2026, Donald A. Denkhaus, an insider of Catalyst Pharmaceuticals, Inc., had all of his equity positions in the company—consisting of 498,773 shares of common stock, multiple tranches of vested stock options, and several series of restricted stock units—disposed of in connection with the closing of the acquisition of Catalyst by Angelini Pharma S.p.A. at a cash merger price of $31.50 per share. His 498,773 outstanding common shares were effectively cashed out at $31.50 per share, implying gross consideration of approximately $15.7 million. All reported stock options, with exercise prices ranging from $3.42 to $22.77, were cancelled and converted into the right to receive a cash payment equal to $31.50 minus the applicable exercise price, multiplied by the number of option shares, producing estimated aggregate option value of roughly $2.3 million. In addition, his restricted stock units (RSUs) covering 8,776 shares (1,414 + 1,894 + 5,468) vested in full at closing and were cancelled for a cash payment equal to $31.50 per unit, implying about $276,000 in value. As a result of the merger consideration being paid wholly in cash and all equity awards being cancelled for cash, Denkhaus no longer holds any Catalyst equity following the transaction.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000175

Alert Tier

7